Upgrade to SI Premium - Free Trial

Regeneron Pharma (REGN) PT Lowered to $880 at Leerink Partners

November 1, 2024 7:19 AM
Leerink Partners analyst Andrew Berens lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $880.00 (from $1,077.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change

Next Articles